BRAF and RAS mutations as prognostic factors in metastatic colorectal cancer patients undergoing liver resection

British Journal of Cancer

Volumn 112, Issue 12, 2015, Pages 1921-1928

  Schirripa, M ^a   Bergamo, F ^b   Cremolini, C ^a   Casagrande, M ^c   Lonardi, S ^b   Aprile, G ^c   Yang, Dongyun ^d   Marmorino, F ^a   Pasquini, G ^a   Sensi, E ^e   Lupi, C ^e   De Maglio, G ^c   Borrelli, N ^e   Pizzolitto, S ^c   Fasola, G ^c   Bertorelle, R ^b   Rugge, M ^f   Fontanini, G ^e   Zagonel, V ^b   Loupakis, F ^a   Falcone, A ^a   more..

^a UNIVERSITY HOSPITAL OF PISA   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e UNIVERSITY OF PISA   (Italy)

^f UNIVERSITY HOSPITAL OF PADOVA   (Italy)

Author keywords

BRAF; liver; metastatic colorectal cancer; prognostic; RAS

Indexed keywords

B RAF KINASE; RAS PROTEIN; BRAF PROTEIN, HUMAN; TUMOR MARKER;

AGED; ARTICLE; CANCER PROGNOSIS; CLINICAL FEATURE; FEMALE; GENE MUTATION; GENOTYPE; HIGH RISK POPULATION; HUMAN; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METASTATIC COLORECTAL CANCER; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PRIORITY JOURNAL; PYROSEQUENCING; RECURRENCE FREE SURVIVAL; COLORECTAL TUMOR; DISEASE FREE SURVIVAL; ENZYMOLOGY; GENETICS; LIVER NEOPLASMS; MIDDLE AGED; MUTATION; ONCOGENE RAS; PATHOLOGY; PROGNOSIS; SECONDARY;

AGED; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENES, RAS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84930865716     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.142     Document Type: Article

References (37)

1. National Comprehensive Cancer Network. http://www.nccn.org/professionals/physician-gls/pdf/colon.pdf.
2. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, Patterson SD, Chang DD (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26(10): 1626-1634.
3. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, O'Donoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lovig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N (2001) Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study. Br J Cancer 85(5): 692-696.
4. Cejas P, Lopez-Gomez M, Aguayo C, Madero R, de Castro Carpeno J, Belda-Iniesta C, Barriuso J, Moreno Garcia V, Larrauri J, Lopez R, Casado E, Gonzalez-Baron M, Feliu J (2009) KRAS mutations in primary colorectal cancer tumors and related metastases: a potential role in prediction of lung metastasis. PLoS One 4(12): e8199.
5. de Jong MC, Pulitano C, Ribero D, Strub J, Mentha G, Schulick RD, Choti MA, Aldrighetti L, Capussotti L, Pawlik TM (2009) Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg 250(3): 440-448.
6. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocakova I, Ruff P, Blasinska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD (2013) Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 369(11): 1023-1034.
7. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230(3): 309-318 discussion 318-21.
8. Goldstein J, Tran B, Ensor J, Gibbs P, Wong HL, Wong SF, Vilar E, Tie J, Broaddus R, Kopetz S, Desai J, Overman M (2014) Multicenter retrospective analysis of metastatic colorectal cancer (CRC) with high-level microsatellite instability (MSI-H). Ann Oncol 25(5): 1032-1038.
9. Hayashi M, Inoue Y, Komeda K, Shimizu T, Asakuma M, Hirokawa F, Miyamoto Y, Okuda J, Takeshita A, Shibayama Y, Tanigawa N (2010) Clinicopathological analysis of recurrence patterns and prognostic factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg 10: 27.
10. Karagkounis G, Torbenson MS, Daniel HD, Azad NS, Diaz Jr. LA, Donehower RC, Hirose K, Ahuja N, Pawlik TM, Choti MA (2013) Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases. Cancer 119(23): 4137-4144.
11. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR (2008) K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359(17): 1757-1765.
12. Kemeny N, Chou J, Capanu M, Gewirtz A, Cercek A, Kingham P, Jarnagin WR, Fong Y, DeMatteo RP, Allen PJ, Shia J, Ang C, Vakiani E, D'Angelica M (2013) Association of KRAS mutation with worse recurrence-free survival and site of metastatic progression after resection of hepatic colorectal metastases. J Clin Oncol 31(suppl; abstr 3609).
13. Kim MJ, Lee HS, Kim JH, Kim YJ, Kwon JH, Lee JO, Bang SM, Park KU, Kim DW, Kang SB, Kim JS, Lee JS, Lee KW (2012) Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer. BMC Cancer 12: 347.
14. Kopetz S, Chang GJ, Overman MJ, Eng C, Sargent DJ, Larson DW, Grothey A, Vauthey JN, Nagorney DM, McWilliams RR (2009) Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. J Clin Oncol 27(22): 3677-3683.
15. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P (2006) KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 66(8): 3992-3995.
16. Maithel SK, Ginsberg MS, D'Amico F, DeMatteo RP, Allen PJ, Fong Y, Blumgart LH, Jarnagin WR, D'Angelica MI (2010) Natural history of patients with subcentimeter pulmonary nodules undergoing hepatic resection for metastatic colorectal cancer. J Am Coll Surg 210(1): 31-38.
17. Morris VK, Lucas FA, Overman MJ, Eng C, Morelli MP, Jiang ZQ, Luthra R, Meric-Bernstam F, Maru D, Scheet P, Kopetz S, Vilar E (2014) Clinicopathologic characteristics and gene expression analyses of non-KRAS 12/13, RAS-mutated metastatic colorectal cancer. Ann Oncol 25(10): 2008-2014.
18. Nordlinger B, Guiguet M, Vaillant JC, Balladur P, Boudjema K, Bachellier P, Jaeck D (1996) Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer 77(7): 1254-1262.
19. Peeters M, Oliner KS, Parker A, Siena S, Van Cutsem E, Huang J, Humblet Y, Van Laethem JL, Andre T, Wiezorek J, Reese D, Patterson SD (2013) Massively parallel tumor multigene sequencing to evaluate response to panitumumab in a randomized phase III study of metastatic colorectal cancer. Clin Cancer Res 19(7): 1902-1912.
20. Primrose JN (2010) Surgery for colorectal liver metastases. Br J Cancer 102(9): 1313-1318.
21. Rees M, Tekkis PP, Welsh FK, O'Rourke T, John TG (2008) Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg 247(1): 125-135.
22. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P (2009) KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 27(35): 5931-5937.
23. Saridaki Z, Papadatos-Pastos D, Tzardi M, Mavroudis D, Bairaktari E, Arvanity H, Stathopoulos E, Georgoulias V, Souglakos J (2010) BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients' outcome. Br J Cancer 102(12): 1762-1768.
24. Schirripa M, Cremolini C, Loupakis F, Morvillo M, Bergamo F, Zoratto F, Salvatore L, Antoniotti C, Marmorino F, Sensi E, Lupi C, Fontanini G, Gregorio VD, Giannini R, Basolo F, Masi G, Falcone A (2014) Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer. Int J Cancer 136(1): 83-90.
25. Schmidt GP, Baur-Melnyk A, Haug A, Utzschneider S, Becker CR, Tiling R, Reiser MF, Hermann KA (2009) Whole-body MRI at 1.5T and 3T compared with FDG-PET-CT for the detection of tumour recurrence in patients with colorectal cancer. Eur Radiol 19(6): 1366-1378.
26. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Kohne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A (2012) ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol 23(10): 2479-2516.
27. Stremitzer S, Stift J, Gruenberger B, Tamandl D, Aschacher T, Wolf B, Wrba F, Gruenberger T (2012) KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg 99(11): 1575-1582.
28. Teng HW, Huang YC, Lin JK, Chen WS, Lin TC, Jiang JK, Yen CC, Li AF, Wang HW, Chang SC, Lan YT, Lin CC, Wang HS, Yang SH (2012) BRAF mutation is a prognostic biomarker for colorectal liver metastasectomy. J Surg Oncol 106(2): 123-129.
29. Tie J, Lipton L, Desai J, Gibbs P, Jorissen RN, Christie M, Drummond KJ, Thomson BN, Usatoff V, Evans PM, Pick AW, Knight S, Carne PW, Berry R, Polglase A, McMurrick P, Zhao Q, Busam D, Strausberg RL, Domingo E, Tomlinson IP, Midgley R, Kerr D, Sieber OM (2011) KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res 17(5): 1122-1130.
30. Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, Kemeny N, Brennan MF, Blumgart LH, D'Angelica M (2007) Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol 25(29): 4575-4580.
31. Tran B, Kopetz S, Tie J, Gibbs P, Jiang ZQ, Lieu CH, Agarwal A, Maru DM, Sieber O, Desai J (2011) Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 117(20): 4623-4632.
32. Umeda Y, Nagasaka T, Mori Y, Sadamori H, Sun DS, Shinoura S, Yoshida R, Satoh D, Nobuoka D, Utsumi M, Yoshida K, Yagi T, Fujiwara T (2013) Poor prognosis of KRAS or BRAF mutant colorectal liver metastasis without microsatellite instability. J Hepatobiliary Pancreat Sci 20(2): 223-233.
33. Van Cutsem E, Kohne CH, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S, Schlichting M, Zubel A, Celik I, Rougier P, Ciardiello F (2011) Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 29(15): 2011-2019.
34. Vauthey JN, Kopetz SE (2013) From multidisciplinary to personalized treatment of colorectal liver metastases: 4 reasons to consider RAS. Cancer 119(23): 4083-4085.
35. Vauthey JN, Zimmitti G, Kopetz SE, Shindoh J, Chen SS, Andreou A, Curley SA, Aloia TA, Maru DM (2013) RAS mutation status predicts survival and patterns of recurrence in patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 258(4): 619-626 discussion 626-627.
36. Yaeger R, Cercek A, Chou JF, Sylvester BE, Kemeny NE, Hechtman JF, Ladanyi M, Rosen N, Weiser MR, Capanu M, Solit DB, D'Angelica MI, Vakiani E, Saltz LB (2014) BRAF mutation predicts for poor outcomes after metastasectomy in patients with metastatic colorectal cancer. Cancer 120(15): 2316-2324.
37. Yokota T, Ura T, Shibata N, Takahari D, Shitara K, Nomura M, Kondo C, Mizota A, Utsunomiya S, Muro K, Yatabe Y (2011) BRAF mutation is a powerful prognostic factor in advanced and recurrent colorectal cancer. Br J Cancer 104(5): 856-862.